Insider · CIK 0001815354
Aammaad Shams
officer
Files at EVH (Evolent Health, Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 1, 2026 | EVH Evolent Health, Inc. | FTax withholding Class A Common Stock | -2,577 | $3.25 | $8,375 | 70,322 | Mar 4, 2026 |
| Mar 2, 2026 | EVH Evolent Health, Inc. | AGrant or award Class A Common Stock | +1,686 | $0.00 | $0 | 72,008 | Mar 4, 2026 |
| Mar 2, 2026 | EVH Evolent Health, Inc. | FTax withholding Class A Common Stock | -850 | $3.58 | $3,043 | 71,158 | Mar 4, 2026 |
| Mar 3, 2026 | EVH Evolent Health, Inc. | FTax withholding Class A Common Stock | -4,311 | $3.51 | $15k | 66,847 | Mar 4, 2026 |
| Mar 2, 2026 | EVH Evolent Health, Inc. | AGrant or award Performance-Based Share Unitderivative | +55,173 | $0.00 | $0 | 55,173 | Mar 4, 2026 |
| Aug 1, 2025 | EVH Evolent Health, Inc. | FTax withholding Class A Common Stock | -2,567 | $9.98 | $26k | 72,899 | Aug 5, 2025 |
| Mar 1, 2025 | EVH Evolent Health, Inc. | FTax withholding Class A Common Stock | -5,546 | $8.99 | $50k | 46,833 | Mar 4, 2025 |
| Mar 3, 2025 | EVH Evolent Health, Inc. | AGrant or award Class A Common Stock | +25,151 | $0.00 | $0 | 71,984 | Mar 4, 2025 |
| Mar 3, 2025 | EVH Evolent Health, Inc. | AGrant or award Class A Common Stock | +6,650 | $0.00 | $0 | 78,634 | Mar 4, 2025 |
| Mar 3, 2025 | EVH Evolent Health, Inc. | FTax withholding Class A Common Stock | -3,168 | $8.77 | $28k | 75,466 | Mar 4, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.